Drug-interaction-driven duration describes how another substance changes the PK/PD processes that determine how long sildenafil exposure remains functionally relevant. Within duration drug interactions, the relevant sequence begins with absorption and continues through distribution, metabolism, elimination, and concentration-dependent pharmacodynamic response. The duration definition therefore treats duration as a timing profile rather than a fixed interval. PK/PD basics from pkpd overview provide the framework: an interacting drug can change the input profile described by the onset absorption phase, alter distribution described by the onset distribution phase, modify observed onset plasma levels and the onset cmax relation, or change metabolic decline through onset metabolism impact and onset cyp3a4. These changes can alter the effect window and the timing of threshold crossing represented by time to effect. The resulting profile can differ mechanistically from duration long or duration short classifications, while variability factors and timing consistency describe why the same interaction does not produce identical timing profiles in every setting.
CYP3A4 modulation is especially relevant because sildenafil undergoes substantial hepatic metabolic processing through CYP3A4. A CYP3A4 inhibitor can reduce metabolic clearance, allowing plasma concentrations to decline more slowly and potentially extending exposure persistence. In contrast, a CYP3A4 inducer can increase metabolic processing and accelerate concentration decline, potentially shortening the interval during which exposure remains above a relevant pharmacodynamic threshold. These effects are not simply labels for longer or shorter subjective duration; they are changes in the parameters shaping the concentration-time curve. Other interacting drugs can act upstream or downstream of metabolism. Drugs affecting gastric emptying or intestinal transit can shift absorption timing, while changes in distribution volume or protein binding can alter the movement of sildenafil between plasma and tissues. Hepatic impairment can reduce metabolic capacity, whereas changes in renal handling may influence elimination of sildenafil or metabolites depending on the compound and pathway involved. The resulting duration profile therefore reflects the combined behavior of input, distribution, metabolic clearance, elimination, plasma decline, and pharmacodynamic sensitivity rather than one interaction mechanism alone.
Interaction-driven duration also depends on context. Food or a fatty meal can modify absorption timing, while alcohol, smoking, dosing conditions, age, BMI, and health conditions can modify the background PK/PD state in which an interaction operates. A drug that delays gastric emptying may mainly shift early input and threshold crossing, whereas a metabolic inhibitor may primarily alter the descending portion of the concentration-time curve. A distribution-changing interaction may modify persistence between plasma and peripheral compartments without necessarily producing a proportional change in onset. These distinctions help separate onset from duration: an interaction can delay time to effect while leaving later exposure persistence relatively unchanged, or it can preserve plasma concentrations after onset without substantially changing initial absorption. The mechanistic comparison is therefore better represented by concentration-time behavior, threshold position, and effect-window boundaries than by a single duration label. Interaction effects can increase or decrease timing variability depending on the interacting mechanism, baseline physiology, dose, and concurrent factors, making the observed profile an emergent PK/PD phenotype rather than a fixed property of sildenafil.
Interaction-driven duration begins with the way a second drug changes sildenafil exposure over time. The duration drug interactions framework treats the concentration-time profile as the central mechanistic object, while the duration definition describes how persistence is established by exposure and pharmacodynamic response. An interaction can alter the early concentration rise, peak magnitude, distribution phase, or subsequent decline. Changes in the onset distribution phase may affect how rapidly sildenafil leaves the central plasma compartment and equilibrates with tissues. The resulting onset plasma levels reflect the combined effects of absorption and distribution rather than one pathway in isolation. Likewise, the onset cmax relation provides context for interpreting peak exposure, but Cmax alone does not determine duration. An interaction that reduces clearance can preserve concentrations after the peak, whereas an interaction affecting distribution can modify the shape of the decline. These mechanisms establish how exposure persistence contributes to the later effect window.
CYP3A4 inhibition provides a clear example of an interaction that can shift the descending concentration-time phase. When CYP3A4-mediated metabolic clearance is reduced, sildenafil may remain in the systemic circulation longer, producing slower plasma decline and greater exposure persistence. The duration effect therefore emerges from altered elimination kinetics rather than from a separate duration mechanism. The duration drug interactions concept includes this clearance effect alongside distribution and absorption changes. The onset plasma levels can remain elevated for longer, while the onset cmax relation helps distinguish a higher peak from a prolonged decline. Distribution can further influence how plasma concentrations behave as sildenafil exchanges between compartments, making the onset distribution phase relevant beyond onset itself. The resulting effect window depends on when exposure crosses a functional PD threshold. Thus, slower decline may extend the timing profile without implying a fixed or universal duration.
A CYP3A4 inducer provides the contrasting mechanistic pattern. Increased metabolic processing can raise clearance and accelerate the downward portion of the concentration-time curve, reducing exposure persistence and potentially moving threshold crossing earlier. This differs from simply assigning a case to duration short, because the short profile has a specific mechanistic basis linked to enhanced clearance. Conversely, reduced clearance can contribute to duration long, but a long profile can also arise from distribution persistence, altered input, or other PK/PD factors. The duration definition therefore remains broader than any individual interaction. The relationship between peak exposure and persistence is also important: a higher Cmax does not necessarily mean proportionally longer duration, and a lower Cmax does not automatically mean a short effect window. Interaction-driven duration is best interpreted by examining absorption, distribution, plasma decline, clearance, and threshold position together. This approach keeps the duration drug interactions concept mechanistic and distinguishes exposure persistence from subjective duration descriptions.
| Mechanism | PK Change | Duration Interpretation |
|---|---|---|
| CYP3A4 inhibition | Reduced metabolic clearance | Slower plasma decline and potentially greater exposure persistence |
| CYP3A4 induction | Increased metabolic clearance | Faster decline and potentially shorter exposure persistence |
| Distribution alteration | Changed compartmental movement or distribution volume | Modified plasma persistence and concentration-time shape |
| Absorption alteration | Changed input rate or lag | Shifted early exposure and threshold-crossing timing |
Not all interaction-driven duration changes originate in hepatic metabolism. Some interacting conditions alter the rate at which sildenafil enters systemic circulation, changing the initial concentration-time profile and the timing of later exposure. The onset food impact framework describes how food can shift absorption kinetics, while onset fatty-food delay focuses on delayed or redistributed input associated with a high-fat meal. Changes in onset gastric emptying can similarly alter how quickly drug reaches the intestine and becomes available for absorption. These effects are represented within the onset absorption phase, but their consequences can extend into duration when altered input changes the entire concentration-time curve. The resulting onset plasma levels may rise more slowly, reach a different peak, or shift the timing of threshold crossing. Consequently, an interaction affecting absorption should not automatically be interpreted as increasing or decreasing total duration. Its primary effect may instead be a temporal displacement of exposure, with later phases determined by distribution and clearance.
Gastric-emptying and GI-transit interactions illustrate why onset and duration should remain separate PK/PD constructs. If gastric emptying is delayed, sildenafil may reach its principal absorption site later, producing a slower early concentration rise. The onset gastric emptying mechanism can therefore shift threshold crossing without necessarily changing the terminal elimination process. A fatty meal may produce a related input shift through onset fatty-food delay, while broader onset food impact can include changes in absorption rate and timing. The onset absorption phase provides the mechanistic location of these effects. Once sildenafil has entered systemic circulation, onset plasma levels are shaped by distribution and metabolic clearance. Therefore, an input interaction can produce a delayed onset without proportionally extending the later effect window. Conversely, a prolonged input profile can broaden exposure timing if absorption remains relevant while elimination is already occurring. These patterns show why interaction effects must be interpreted across the complete concentration-time sequence.
Food, alcohol, smoking, dosing conditions, and interacting medicines can also overlap rather than operate independently. A food-related change in absorption may coincide with a CYP3A4 interaction, producing a concentration-time profile that differs from either factor alone. Likewise, an interaction affecting gastric emptying can alter early exposure while a metabolic interaction simultaneously changes the rate of plasma decline. The onset food impact, onset fatty-food delay, and onset gastric emptying concepts therefore describe input-side mechanisms that can interact with downstream clearance. The onset absorption phase identifies when the input difference occurs, while onset plasma levels show its concentration-time consequence. Mechanistically, the final duration profile reflects the balance between how sildenafil enters, distributes, and leaves the system. This explains why identical interaction labels can correspond to different timing patterns when food state, dose, physiology, or concurrent metabolic effects differ.
| Interaction Determinant | PK Basis | Timing Impact |
|---|---|---|
| Food intake | Altered absorption conditions and input rate | May shift early exposure and threshold-crossing timing |
| Fatty meal | Delayed or redistributed gastrointestinal input | May delay concentration rise and onset timing |
| Gastric emptying | Changed delivery of sildenafil to intestinal absorption sites | Can shift the absorption phase and early plasma profile |
| GI transit | Changed movement through the gastrointestinal tract | Can alter input timing and concentration-time formation |
| Concurrent metabolic interaction | Modified clearance during or after absorption | Can alter persistence independently of early input timing |
Early PK/PD dynamics establish the starting conditions from which interaction-driven duration develops. After administration, sildenafil enters the circulation according to the absorption profile, then undergoes distribution and metabolic processing. The onset plasma levels construct captures the resulting concentration-time rise, while the onset distribution phase describes movement from the central compartment into tissues. An interaction that changes either process can alter the concentration available for pharmacodynamic activity at a given time. The onset cmax relation helps characterize peak exposure, but peak concentration must be interpreted alongside the subsequent decline. The onset metabolism impact framework becomes particularly important when an interacting drug changes hepatic metabolic activity. CYP3A4 modulation, described through onset cyp3a4, can alter the rate at which sildenafil is removed from plasma. The timing of functional threshold crossing, represented by time to effect, therefore emerges from the combined input, distribution, clearance, and PD response processes.
CYP3A4 inhibition and induction demonstrate how early and late phases can become mechanistically connected. Reduced CYP3A4 activity can slow sildenafil metabolism, causing plasma levels to remain elevated for longer after absorption has occurred. Increased CYP3A4 activity can produce the opposite pattern by accelerating metabolic clearance and reducing exposure persistence. The onset cyp3a4 pathway therefore has implications beyond onset itself, because metabolic processing shapes the descending concentration-time curve. The onset metabolism impact concept identifies this pathway, while onset plasma levels reveal the observable concentration consequence. Distribution remains relevant because plasma concentration reflects exchange between compartments, as described by the onset distribution phase. The onset cmax relation should consequently be separated from persistence: a peak may be higher or lower without establishing the duration of exposure above a PD threshold. Threshold timing through time to effect depends on the full PK/PD trajectory.
An interaction can therefore modify duration without producing a proportionate change in onset, and it can modify onset without substantially changing the later elimination phase. For example, a gastric interaction may delay the rise in onset plasma levels while leaving CYP3A4-mediated clearance essentially unchanged. A metabolic inhibitor may instead leave absorption timing relatively similar while slowing the subsequent decline. Distribution effects can further separate plasma measurements from tissue exposure, making the onset distribution phase relevant to both early and later interpretation. The onset cmax relation provides peak context but does not independently define an effect window. Likewise, onset metabolism impact and onset cyp3a4 describe metabolic determinants rather than a subjective duration endpoint. The resulting time to effect and later offset are separate timing features of the same concentration-response trajectory. This separation is essential when interpreting interaction-driven duration mechanistically rather than treating every timing change as a single duration variable.
| PK/PD Process | Interaction Effect | Timing Consequence |
|---|---|---|
| Absorption | Changed input rate or lag | Alters early concentration rise and threshold timing |
| Distribution | Changed compartmental movement | Modifies plasma persistence and concentration profile |
| CYP3A4 metabolism | Inhibition or induction of metabolic activity | Changes clearance and plasma decline |
| Elimination | Altered systemic removal | Shifts exposure persistence and offset timing |
| PD threshold | Changed exposure-response relationship | Changes the time at which functional response crosses a threshold |
Interaction-driven timing is easier to interpret when onset and duration are treated as separate segments of the same concentration-time profile. A slow rise in concentration may produce onset slow timing, while a rapid rise may produce onset fast timing. Neither pattern alone establishes how long sildenafil remains above a relevant PD threshold. The onset vs duration basics framework separates the initial threshold-crossing phase from the later persistence and decline phase. On a concentration-time representation, the onset vs duration graph can show whether an interaction primarily shifts the rising limb, the peak, the descending limb, or multiple phases. The duration definition then identifies duration from the persistence of exposure and response rather than from the onset point alone. A gastric interaction may move the rising limb to the right, whereas a CYP3A4 inhibitor may flatten the descending limb. These are distinct mechanistic changes even when both alter the observed timing profile.
A slow-onset interaction can occur when gastric emptying, intestinal transit, or another input process delays systemic exposure. In such a case, threshold crossing may occur later, but the elimination phase may retain its underlying rate. Conversely, an interaction that inhibits CYP3A4 can preserve exposure after the peak, potentially shifting the offset later without substantially moving the initial absorption phase. The onset slow and onset fast constructs therefore describe the early portion of timing, while onset vs duration basics provides the conceptual separation needed to interpret later persistence. The onset vs duration graph can make these differences visible by distinguishing movement of the rising curve from changes in the declining curve. Under the duration definition, an interaction-driven duration shift is therefore identified by how the exposure-response trajectory changes, not simply by whether onset appears earlier or later.
Long and short duration patterns can arise from many mechanisms, so an interaction should not be treated as synonymous with either category. A CYP3A4 inhibitor may contribute to a duration long profile when reduced clearance sustains exposure, but distribution persistence or other PK factors can also contribute. A CYP3A4 inducer may contribute to a duration short profile through faster clearance, but a short profile can also reflect lower exposure, altered input, or PD threshold position. The onset vs duration basics framework keeps these mechanisms distinct. Graphically, the onset vs duration graph can distinguish a shifted rising limb from a prolonged or abbreviated declining limb. This matters because two profiles can share the same onset yet have different offsets, or share a similar offset while differing in onset. The duration definition therefore treats interaction-driven duration as an emergent PK/PD timing profile rather than a fixed property of the drug.
| Timing Component | PK/PD Basis | Interpretation |
|---|---|---|
| Early rise | Absorption rate and input timing | Primarily describes onset rather than total duration |
| Peak exposure | Cmax and distribution balance | Defines peak concentration but not duration by itself |
| Descending phase | Metabolic clearance and elimination | Strongly influences exposure persistence and offset |
| Threshold crossing | Concentration relative to PD sensitivity | Defines entry into or exit from a functional response range |
| Effect-window span | Combined exposure and PD response trajectory | Represents the timing interval between functional boundaries |
Interaction-driven duration varies because the interacting drug operates within an existing physiological PK/PD system. The variability factors framework includes absorption, distribution, metabolic clearance, elimination, and PD sensitivity, all of which can influence the final concentration-time profile. Age-related changes described by duration age impact can alter metabolic capacity or distribution, while BMI-related differences described by duration bmi impact can modify distribution and clearance relationships. Health conditions represented by duration health conditions may additionally change hepatic, renal, cardiovascular, or gastrointestinal processes relevant to exposure. These baseline differences can amplify or attenuate the apparent effect of an interacting drug. Alcohol and smoking may introduce additional physiological or metabolic context through onset alcohol and onset smoking. Consequently, an interaction should be understood as a modifier of an existing PK/PD profile rather than as an isolated determinant with an identical effect across all individuals.
Timing consistency describes how reproducibly a concentration-time profile follows similar temporal behavior under comparable conditions. The timing consistency concept is affected when interacting drugs alter absorption, clearance, or distribution in ways that vary with dose, co-medications, food state, physiology, or metabolic phenotype. The clinical timing framework can describe the practical timing context, but the underlying mechanistic explanation remains PK/PD-based. Age through duration age impact, BMI through duration bmi impact, and health conditions through duration health conditions can all change the baseline against which an interaction is observed. Alcohol and smoking may add further variability through onset alcohol and onset smoking. The result can be greater dispersion in onset, exposure persistence, or offset timing. This is why an interaction label alone does not uniquely determine a duration profile.
Dose and concurrent conditions provide additional context for interaction-driven variability. The amount administered affects the starting concentration-time trajectory, while duration age impact and duration bmi impact can modify distribution or clearance parameters. Health conditions represented by duration health conditions may alter hepatic or renal elimination, potentially changing how strongly an interacting drug affects exposure persistence. Alcohol and smoking can contribute additional variability through onset alcohol and onset smoking. The broader variability factors framework therefore treats interaction effects as context-dependent changes to an already variable system. The resulting timing consistency depends on whether the same input, distribution, metabolic, and PD conditions recur. clinical timing can summarize when events occur, but mechanistic interpretation requires identifying which PK or PD parameter changed and how that parameter altered threshold crossing, exposure persistence, or offset.
| Context Factor | Mechanistic Interaction | Timing Variability |
|---|---|---|
| Age | May alter metabolic capacity and distribution | Can change clearance and exposure persistence |
| BMI | Can influence distribution and clearance relationships | May shift concentration decline and duration profile |
| Health conditions | Can modify hepatic, renal, GI, or cardiovascular processes | May alter absorption, clearance, or threshold timing |
| Alcohol | Adds physiological and contextual PK/PD variability | Can contribute to differences in timing profiles |
| Smoking | May alter metabolic or physiological context | Can contribute to inter-individual timing variation |
Drug interactions can modify sildenafil duration by changing one or more PK/PD processes that determine exposure persistence. An interacting drug may alter absorption, gastric emptying, distribution, metabolic clearance, elimination, or plasma protein binding. CYP3A4 inhibitors can reduce metabolic clearance, allowing sildenafil concentrations to decline more slowly and potentially extending exposure persistence. CYP3A4 inducers can increase metabolic processing, accelerating plasma decline and potentially shortening persistence. Other interactions may primarily shift absorption timing without substantially changing elimination. The final duration profile therefore depends on the concentration-time curve and the pharmacodynamic threshold relevant to response. An interaction does not create a separate duration mechanism; it modifies parameters within the existing PK/PD system. The observed timing can consequently differ according to dose, physiology, concurrent factors, and the specific mechanism of the interacting drug.
Interaction-driven duration varies because the same interacting drug can act on different underlying PK/PD systems. Individuals may differ in absorption rate, gastric emptying, distribution volume, metabolic activity, clearance, hepatic function, renal handling, protein binding, and pharmacodynamic sensitivity. A CYP3A4 inhibitor may therefore produce a different change in plasma decline when baseline metabolic clearance differs. Similarly, a drug affecting absorption can have a different timing effect when gastric emptying or intestinal transit already varies. Age, BMI, health conditions, food state, alcohol, smoking, dose, and other interacting substances can further modify the concentration-time trajectory. These factors do not necessarily determine duration independently; they interact with the primary mechanism. Consequently, an interaction should be interpreted as a modifier of exposure and response dynamics rather than as a fixed number of additional or fewer hours.
Plasma decline reflects the combined effects of distribution, metabolism, and elimination after sildenafil reaches systemic circulation. An interacting drug can alter this decline by changing metabolic clearance, distribution between compartments, or other elimination processes. CYP3A4 inhibition is a principal example: reduced metabolic activity can slow sildenafil clearance and produce a more persistent concentration-time profile. CYP3A4 induction can have the opposite effect by increasing metabolic processing and accelerating decline. Distribution changes can also modify the apparent shape of the plasma curve because sildenafil may move between central and peripheral compartments. An interaction affecting absorption may change the earlier rising portion without substantially changing the later decline. Therefore, plasma decline should be evaluated as one phase of the complete PK trajectory. Its timing helps explain exposure persistence and offset, but it does not independently establish pharmacodynamic effectiveness or a fixed subjective duration.
Distribution persistence describes how sildenafil exchanges between plasma and tissue compartments over time. An interacting drug that changes distribution volume, protein binding, or compartmental movement can alter the relationship between measured plasma concentration and the broader exposure profile. This may influence the shape of the concentration-time curve even when metabolic clearance remains unchanged. Distribution is particularly relevant during the transition from the early concentration rise toward the later declining phase. A change in distribution can modify the apparent persistence of plasma levels, but it does not automatically imply a longer pharmacodynamic effect. The functional duration still depends on exposure relative to PD sensitivity and threshold position. Distribution therefore acts alongside absorption, metabolism, and elimination rather than replacing them. Interaction-driven duration is best understood as the combined result of these processes, with distribution persistence contributing to how exposure moves through and leaves the relevant compartments.
Duration offset represents the later point at which the exposure-response trajectory moves below a defined functional threshold. During a drug interaction, offset timing can shift when plasma decline changes, metabolic clearance is altered, distribution persistence changes, or pharmacodynamic sensitivity differs. A CYP3A4 inhibitor may slow metabolic clearance and therefore delay the concentration decline toward the relevant threshold. A CYP3A4 inducer may accelerate clearance and move that crossing earlier. An absorption interaction may change the starting trajectory without necessarily producing a proportional offset change. Distribution can further influence the relationship between plasma concentration and tissue exposure. Because offset is threshold-dependent, it cannot be determined from a single plasma concentration or half-life value alone. The mechanistic interpretation therefore considers the entire concentration-time curve, the relevant PD response relationship, and the interaction's effect on clearance or distribution.
Interaction-driven duration describes the mechanism producing a timing change, whereas long or short duration describes the resulting position or spread of the timing profile. A CYP3A4 inhibitor may contribute to a longer exposure profile by slowing metabolic clearance, while a CYP3A4 inducer may contribute to a shorter profile by accelerating clearance. However, long duration can also result from other factors such as distribution persistence or altered exposure, and short duration can arise from lower exposure, faster elimination, or pharmacodynamic threshold differences. The terms therefore should not be treated as interchangeable. An interaction identifies a causal PK/PD modifier, while long or short duration describes the observed timing phenotype. The distinction is important because the same duration category can arise through different mechanisms. Mechanistic interpretation requires identifying whether absorption, distribution, metabolism, elimination, or PD sensitivity changed.
Pharmacokinetics describes how sildenafil enters, distributes through, and leaves the body, while pharmacodynamics describes how the resulting exposure relates to response. Interaction-driven duration emerges from the connection between these two domains. Absorption establishes the input profile, distribution changes compartmental concentrations, metabolism and elimination determine plasma decline, and PD sensitivity determines how exposure translates into a functional response. A drug interaction can modify any of these processes. CYP3A4 inhibitors primarily affect metabolic clearance, whereas CYP3A4 inducers can accelerate it. Gastric-emptying or GI interactions primarily influence absorption timing. Distribution or protein-binding interactions can modify concentration relationships between plasma and tissues. Duration therefore reflects exposure persistence relative to a PD threshold rather than concentration alone. Onset and offset are separate timing features within the same trajectory, so an interaction can alter one phase without proportionally changing the other.
Relevant variability factors include absorption rate, gastric emptying, intestinal transit, food state, distribution volume, protein binding, hepatic metabolic activity, CYP3A4 activity, clearance, renal function, age, BMI, health conditions, dose, alcohol, smoking, and concurrent medications. Their importance depends on the mechanism of the interaction. For a CYP3A4 inhibitor, baseline metabolic clearance and hepatic processing may strongly influence the change in exposure persistence. For a gastric-emptying interaction, gastrointestinal timing may be more relevant to the early concentration profile. Distribution-related differences can modify plasma persistence, while pharmacodynamic sensitivity can alter the exposure level associated with a functional response. These factors can also interact with each other, making the resulting duration profile multidimensional. Consequently, no single variability factor universally determines interaction-driven duration. The mechanistic profile emerges from how the interacting drug changes the existing PK/PD parameters under the surrounding physiological conditions.
Timing consistency can change when an interacting drug introduces additional variability into absorption, metabolism, distribution, or elimination. If the interaction consistently reduces CYP3A4 activity, the concentration decline may shift in a relatively reproducible direction under comparable conditions. However, differences in dose timing, food intake, gastric emptying, concurrent medicines, metabolic phenotype, hepatic function, or other physiological conditions can change the magnitude of that effect. An absorption interaction may be particularly sensitive to meal composition or gastrointestinal transit, while a metabolic interaction may depend more strongly on baseline clearance. The resulting variability can affect onset, exposure persistence, threshold crossing, and offset separately. Timing consistency therefore describes the reproducibility of the complete PK/PD timing profile rather than a guarantee of a fixed duration. Repeatedly similar conditions tend to reduce contextual variability, while changing interaction conditions can broaden the observed distribution of timing outcomes.
Clinical timing describes when observable pharmacological events occur in a practical context, while interaction-driven duration provides the mechanistic PK/PD explanation for those timing changes. An interaction may delay onset by altering gastric emptying or absorption, or it may extend exposure persistence by reducing metabolic clearance. A CYP3A4 inducer may instead accelerate plasma decline and shift offset earlier. Age, BMI, health conditions, food, alcohol, smoking, dose, and other medicines can modify these effects by changing the underlying PK/PD environment. Clinical timing can therefore show that two timing profiles differ, but mechanistic interpretation requires identifying the processes responsible for the difference. The relevant sequence includes absorption, distribution, plasma concentration, metabolism, elimination, and PD threshold relationships. Because onset and duration are distinct constructs, an interaction can alter early timing without proportionally changing later persistence, or alter offset while leaving the initial onset trajectory relatively similar.